Habitable Zones of Host Stars During the Post-MS Phase

A star will become brighter and brighter with stellar evolution, and the distance of its habitable zone will become farther and farther. Some planets outside the habitable zone of a host star during the main sequence phase may enter the habitable zone of the host star during other evolutionary phases. A terrestrial planet within the habitable zone of its host star is generally thought to be suited to life existence. Furthermore, a rocky moon around a giant planet may be also suited to life survive, provided that the planet-moon system is within the habitable zone of its host star. Using Eggleton's code and the boundary flux of habitable zone, we calculate the habitable zone of our Solar after the main sequence phase. It is found that Mars' orbit and Jupiter's orbit will enter the habitable zone of Solar during the subgiant branch phase and the red giant branch phase, respectively. And the orbit of Saturn will enter the habitable zone of Solar during the He-burning phase for about 137 million years. Life is unlikely at any time on Saturn, as it is a giant gaseous planet. However, Titan, the rocky moon of Saturn, may be suitable for biological evolution and become another Earth during that time. For low-mass stars, there are similar habitable zones during the He-burning phase as our Solar, because there are similar core masses and luminosities for these stars during that phase.Comment: 6 pages, 7 figures. Accepted by Ap & S

Habitable Zones and UV Habitable Zones around Host Stars

Ultraviolet radiation is a double-edged sword to life. If it is too strong, the terrestrial biological systems will be damaged. And if it is too weak, the synthesis of many biochemical compounds can not go along. We try to obtain the continuous ultraviolet habitable zones, and compare the ultraviolet habitable zones with the habitable zones of host stars. Using the boundary ultraviolet radiation of ultraviolet habitable zone, we calculate the ultraviolet habitable zones of host stars with masses from 0.08 to 4.00 \mo. For the host stars with effective temperatures lower than 4,600 K, the ultraviolet habitable zones are closer than the habitable zones. For the host stars with effective temperatures higher than 7,137 K, the ultraviolet habitable zones are farther than the habitable zones. For hot subdwarf as a host star, the distance of the ultraviolet habitable zone is about ten times more than that of the habitable zone, which is not suitable for life existence.Comment: 5 pages, 3 figure

Multiomics and blood-based biomarkers of moyamoya disease: protocol of Moyamoya Omics Atlas (MOYAOMICS)

Abstract Background Moyamoya disease (MMD) is a rare and complex cerebrovascular disorder characterized by the progressive narrowing of the internal carotid arteries and the formation of compensatory collateral vessels. The etiology of MMD remains enigmatic, making diagnosis and management challenging. The MOYAOMICS project was initiated to investigate the molecular underpinnings of MMD and explore potential diagnostic and therapeutic strategies. Methods The MOYAOMICS project employs a multidisciplinary approach, integrating various omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, to comprehensively examine the molecular signatures associated with MMD pathogenesis. Additionally, we will investigate the potential influence of gut microbiota and brain-gut peptides on MMD development, assessing their suitability as targets for therapeutic strategies and dietary interventions. Radiomics, a specialized field in medical imaging, is utilized to analyze neuroimaging data for early detection and characterization of MMD-related brain changes. Deep learning algorithms are employed to differentiate MMD from other conditions, automating the diagnostic process. We also employ single-cellomics and mass cytometry to precisely study cellular heterogeneity in peripheral blood samples from MMD patients. Conclusions The MOYAOMICS project represents a significant step toward comprehending MMD’s molecular underpinnings. This multidisciplinary approach has the potential to revolutionize early diagnosis, patient stratification, and the development of targeted therapies for MMD. The identification of blood-based biomarkers and the integration of multiple omics data are critical for improving the clinical management of MMD and enhancing patient outcomes for this complex disease